Glenmark Pharma and OMRON Healthcare India Team Up to Combat Hypertension Ignorance among Young Adults in India

Chandigarh, August 11, 2023: Glenmark Pharmaceuticals Limited (Glenmark), a leading, integrated, research-led global pharmaceutical company has joined hands with OMRON Healthcare India, the Indian arm of the Japanese global leader in home blood pressure monitoring and solutions for cardiovascular disease management, to raise awareness on measuring blood pressure at home from the age of 18.

The lack of specific guidelines on the right age to begin blood pressure screening has led to neglect in initiating checks, leaving many individuals vulnerable to hypertension and its complications. In response to this critical issue, Glenmark initiated discussions with 94 cardiologists across India, leading to a unanimous consensus that 18 is the ideal age to commence blood pressure screening. This expert consensus statement was published in the Journal of the Association of Physicians of India (JAPI) in 2020.

Speaking about this collaboration, Alok Malik, Executive Vice President & Head of India Formulations,Glenmark Pharmaceuticals Ltd., said, "As leaders in hypertension therapy, we are dedicated to making a positive impact on public health. Our collaboration with OMRON HealthcareIndia is a testament to our commitment to raise awareness about hypertension and early blood pressure screening. There has been a concerning rise in the incidence of hypertension among young adults in India, with about 10-30% of young adults (<40 years of age) suffering from high blood pressure in the country. Together, we aim to empower individuals to proactively safeguard their health from a young age.”

Tetsuya Yamada, Managing Director, OMRON Healthcare India said, “Partnering with Glenmark Pharmaceuticals for the 'Take Charge @18' campaign aligns perfectly with our vision of ‘Going for Zero Promoting home blood pressure monitoring as one of the key preventive healthcare practices to significantly reduce hypertension-led diseases such as stroke and heart failure. Our internal studies indicate that the penetration rate of blood pressure monitors usage amongsthypertensive patients in India remains low at around 2% only. By integrating the campaign's message into our products and services we aim to inspire millions to lead healthier lives.”